Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Fastenau

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 22, 2024
A landscape review to identify what matters to patients with thrombotic cardiovascular diseases and patient-reported outcome instruments which can be used to capture the patient experienceAlexandra I Barsdorf, John Fastenau, Shannon Lee, et al.
BMC Psychiatry|September 11, 2013
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisMarie-Hélène Lafeuille, François Laliberté-Auger, Patrick Lefebvre, et al.
Journal of Comparative Effectiveness Research|July 15, 2015
Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patientsYongling Xiao, Erik Muser, Marie-Hélène Lafeuille, et al.
Journal of Medical Economics|September 7, 2013
Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychoticsMarie-Hélène Lafeuille, Jonathan Gravel, Patrick Lefebvre, et al.
Current Medical Research and Opinion|April 16, 2014
Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophreniaMarie-Hélène Lafeuille, Jason Dean, Valerie Carter, et al.
Journal of Medical Economics|April 9, 2015
Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvementErik Muser, Chris M Kozma, Carmela J Benson, et al.
The Clinical Respiratory Journal|December 25, 2025
Impact of Bronchiectasis on Healthcare Resource Utilization and Direct Medical Costs of Managing Comorbid Chronic Obstructive Pulmonary Disease, Asthma, and Rheumatoid Arthritis in the United StatesMaitreyee Mohanty, Fei Tang, John Fastenau, et al.
The American Journal of Managed Care|June 9, 2016
Medicaid managed care penetration and drug utilization for patients with serious mental illnessAaron L Schwartz, Jacqueline Pesa, Dilesh Doshi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 6, 2014
Burden of schizophrenia on selected comorbidity costsMarie-Hélène Lafeuille, Jason Dean, John Fastenau, et al.
American Health & Drug Benefits|December 21, 2016
Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with SchizophreniaMarie-Hélène Lafeuille, Christian Frois, Michel Cloutier, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 22, 2024
A landscape review to identify what matters to patients with thrombotic cardiovascular diseases and patient-reported outcome instruments which can be used to capture the patient experienceAlexandra I Barsdorf, John Fastenau, Shannon Lee, et al.
BMC Psychiatry|September 11, 2013
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisMarie-Hélène Lafeuille, François Laliberté-Auger, Patrick Lefebvre, et al.
Journal of Comparative Effectiveness Research|July 15, 2015
Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patientsYongling Xiao, Erik Muser, Marie-Hélène Lafeuille, et al.
Journal of Medical Economics|September 7, 2013
Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychoticsMarie-Hélène Lafeuille, Jonathan Gravel, Patrick Lefebvre, et al.
Current Medical Research and Opinion|April 16, 2014
Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophreniaMarie-Hélène Lafeuille, Jason Dean, Valerie Carter, et al.
Journal of Medical Economics|April 9, 2015
Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvementErik Muser, Chris M Kozma, Carmela J Benson, et al.
The Clinical Respiratory Journal|December 25, 2025
Impact of Bronchiectasis on Healthcare Resource Utilization and Direct Medical Costs of Managing Comorbid Chronic Obstructive Pulmonary Disease, Asthma, and Rheumatoid Arthritis in the United StatesMaitreyee Mohanty, Fei Tang, John Fastenau, et al.
The American Journal of Managed Care|June 9, 2016
Medicaid managed care penetration and drug utilization for patients with serious mental illnessAaron L Schwartz, Jacqueline Pesa, Dilesh Doshi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 6, 2014
Burden of schizophrenia on selected comorbidity costsMarie-Hélène Lafeuille, Jason Dean, John Fastenau, et al.
American Health & Drug Benefits|December 21, 2016
Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with SchizophreniaMarie-Hélène Lafeuille, Christian Frois, Michel Cloutier, et al.
Pageof 5